Core Insights - China Resources Pharmaceutical (03320) reported a mid-year performance for 2025, achieving revenue of RMB 131.867 billion, a year-on-year increase of 2.54% [1] - The company's profit attributable to equity shareholders was RMB 2.077 billion, a decrease of 20.25% year-on-year, with earnings per share at RMB 0.33 and an interim dividend proposed at RMB 0.072 per share [1] - The gross profit for the reporting period was RMB 21.5096 billion, up 2.8% from RMB 20.934 billion in the same period last year, maintaining a gross margin of 16.3% [1] Revenue Breakdown - The revenue contributions from the three main business segments were 16.6% from pharmaceuticals, 79.2% from medical distribution, and 4.2% from retail and other operations [1] - The company has a total of 83 production bases and 561 production lines, producing 944 products, with 555 products included in the national medical insurance catalog and 235 products in the essential drug list [1] Profitability Metrics - Excluding the impact of impairment and other one-off items, the net profit for the reporting period saw a slight decline of 1.3%, while the profit attributable to the company's owners decreased by 4.7% year-on-year [1]

Core Viewpoint - China Resources Pharmaceutical (03320) reported a revenue of RMB 131.867 billion for the first half of 2025, representing a year-on-year increase of 2.54% [1] Financial Performance - The profit attributable to equity shareholders was RMB 2.077 billion, a decrease of 20.25% year-on-year [1] - Earnings per share stood at RMB 0.33, with an interim dividend proposed at RMB 0.072 per share [1] - Gross profit for the period was RMB 21.5096 billion, up 2.8% from RMB 20.934 billion in the same period last year [1] - The overall gross margin remained stable at 16.3%, unchanged from the first half of 2024 [1] - Excluding impairment losses from associates and other one-off items, net profit decreased slightly by 1.3% year-on-year, while profit attributable to the company's owners fell by 4.7% [1] Business Segmentation - Revenue contributions from the three main business segments were as follows: Pharmaceuticals at 16.6%, Medical Distribution at 79.2%, and Retail Pharmacy and Others at 4.2% [1] - As of the end of the reporting period, the company operated 83 production bases and 561 production lines, producing 944 products, of which 555 are included in the National Medical Insurance Catalogue and 235 in the Essential Drug List [1]